OXFORD, England & INGELHEIM, Germany & RIDGEFIELD, Conn. & INDIANAPOLIS, Ind.–(BUSINESS WIRE)–EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a sign…
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
OXFORD, England & INGELHEIM, Germany & RIDGEFIELD, Conn. & INDIANAPOLIS, Ind.–(BUSINESS WIRE)–EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a sign…